Adjuvant therapy for stage I and II non-small cell lung cancer.
The ideal adjuvant program should utilize an effective chemotherapeutic drug (or drug combination) at a maximally tolerated dose for a sufficient time to eradicate all micrometastases. Currently, no such "ideal" program has been identified. Additionally, the optimal timing of a multimodal program has not yet been established (i.e., chemotherapy followed by radiotherapy, or vice versa, or concurrent radiotherapy and chemotherapy). Adjuvant therapy at this time for stage I or II NSCLC should be considered investigational and limited to clinical trials.
Dorr
V J
VJ
Ellis Fischel Cancer Center, University of Missouri, Columbia, USA.
Perry
M C
MC
D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D009367:Neoplasm Staging